Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GPR-ICI

Financiado

Exploration of targeting GPR56 and its cancer cell ligand as a novel immune chec...

Exploration of targeting GPR56 and its cancer cell ligand as a novel immune checkpoint inhibition strategy Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy over the last decade. In essence, ICIs block the interaction of immunosuppressive receptors and their ligands, which attenuate T cell activity and the secretio... ver más

30/11/2024

UCPH

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-11-30

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UCPH

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HOPE Host Protective Engineering of Cancer Immunity by Targeting... 2M€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

RARITY RAtional design of canceR ImmunoTherapY one size does not f... 1M€ Cerrado

TIGITtherapy TIGIT therapy for cancer treatment 150K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2023-05-30
Fecha Fin: 2024-11-30

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy over the last decade. In essence, ICIs block the interaction of immunosuppressive receptors and their ligands, which attenuate T cell activity and the secretion of pro-inflammatory cytokines. Blocking these inhibitory signals results in the release of immunosuppression and promotes anti-tumor T cell reactivity. Unpublished data from our research group, emerging in collaboration with the biotech company InProTher suggests a novel immune checkpoint receptor-ligand pair consisting of an adhesion G protein-coupled receptor (GPCR) and a viral protein. With therapeutic targeting of GPCRs being our main focus, we - together with our collaboration partner InProTher - aim to investigate the blockade of the interaction between immune cells expressing the adhesion GPCR and cancer cells expressing the viral protein as novel ICI and cancer therapy strategy. The exploration of novel immune checkpoints and expanding the repertoire of cancer therapy drugs are paramount for overcoming therapeutic resistance and advancing cancer treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores